Journals Library

An error occurred retrieving publication content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation

{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Isla S Mackenzie 1,*, Christopher J Hawkey 2, Ian Ford 3, Nicola Greenlaw 3, Filippo Pigazzani 1, Amy Rogers 1, Allan D Struthers 1, Alan G Begg 1, Li Wei 4, Anthony J Avery 5, Jaspal S Taggar 5, Andrew Walker 6, Suzanne L Duce 1, Rebecca J Barr 1, Jennifer S Dumbleton 2, Evelien D Rooke 1, Jonathan N Townend 7, Lewis D Ritchie 8, Thomas M MacDonald 1

1 MEMO Research, Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK
2 Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, UK
3 The Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
4 School of Pharmacy, University College London, London, UK
5 Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, , UK
6 Salus Alba, Glasgow, UK
7 Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
8 Academic Primary Care, University of Aberdeen, Aberdeen, UK
* Corresponding author Email: i.s.mackenzie@dundee.ac.uk

Members of the ALL-HEART study group are listed in Appendix 1.

Disclosure of interests

Members of the ALL-HEART study group are listed in Appendix 1.

Full disclosure of interests: Completed ICMJE forms for all authors, including all related interests, are available in the toolkit on the NIHR Journals Library report publication page at https://doi.org/10.3310/ATTM4092.

Primary conflicts of interest: Isla Mackenzie reports research grants from NIHR HTA for the submitted work, research grants from Menarini, EMA, Sanofi, HDR UK, British Heart Foundation and IMI and institutional consultancy income from AstraZeneca outside the submitted work, and personal income from AstraZeneca and Amgen outside the submitted work. She is a member of the NIHR Remote Trial Delivery Group representing the IMI Trials@Home consortium. Christopher Hawkey, Ian Ford, Nicola Greenlaw and Li Wei report research grants from NIHR HTA via University of Dundee to their institutions for the submitted work. Christopher Hawkey declares research funding from NIHR HTA for other work and consultancy income from Kallyopie. Amy Rogers declares membership of the Trial Steering Committee for the DaRe2THINK (healthcare DAta for pragmatic clinical REsearch) trial, which is NIHR funded (NIHR HTA 13/02/80). Allan Struthers reports research grants from NIHR HTA for the submitted work and with the University of Dundee holds a European patent for the use of xanthine oxidase inhibitors in treating chest pain in angina pectoris. Alan Begg reports personal income from Novartis, Mylan, AstraZeneca, Bayer, Daiichi-Sankyo, Boehringer, Pfizer, Galderma, Zambon and Novo-Nordisk outside the submitted work and is a non-remunerated reviewer of cardiovascular applications to NIHR and the Honorary Treasurer of the Scottish Heart and Arterial disease Risk Prevention (SHARP) Society. Anthony Avery declares that he is a Member of the NIHR Programme Grants for Applied Research committee and is a NIHR Senior Investigator (NF-SI-0617-10076). He is also a recipient of research funding from non-commercial sources, mainly NIHR. He is National Clinical Director for Prescribing for NHS England. Jaspal Taggar declares research funding from NIHR and NHS England outside the submitted work, membership of a NICE guideline committee on management of atrial fibrillation, was a panel member for the NIHR RfPB award (2016–9), has received funding for research from the NIHR Clinical Research Network (CRN) East Midlands for the project: increasing engagement with and research opportunities for Eastern European and Ukrainian populations, and is a non-executive director for the Royal Derby and Burton Hospital NHS Trust. Andrew Walker declares personal income for consultancy from Abbvie, Akcea, Albireo, Alexion, Allergan, Amarin, Apsara, Arena, Astellas, AstraZeneca, Autolus, Bayer, Biocryst, Biogen, Biomarin, BMS, Boehringer Ingelheim, Calico, Celgene, Chiesi, Daiichi Sankyo, Diurnal, Elsai, Eli Lilly, Ferring, Galapagos, Gedeon Richter, Gilead, GSK, GW Pharma, Idorsia, Incyte, Intercept, Ionis, Ipsen, Janssen, Jazz, Jcyte, Kite Gilead, LEK, Leo Pharma, Les Laboratories Servier, Lundbeck, Merck (MSD), Merck-Serono, Mitenyi, Mundibiopharma, Mustang Bio, Mylan, Myovant, Norgine, Novartis, Novo Nordisk, Orchard, Paion, Pfizer, Pierre Fabre, PTC, RegenXBio, Rhythm, Sanofi, Santen, Sarepta, SeaGen, Shionogi, Sigmatec, SOBI, Takeda, Tanaya, UCB and Vertex outside the submitted work. Thomas MacDonald reports research grants from NIHR HTA for the submitted work, research grants from Menarini/Ipsen/Teijin, British Heart Foundation, Research Triangle Institute Barcelona, IMI and EMA outside the submitted work, institutional income for consultancy from AstraZeneca and speaker honoraria from Wellcome Trust outside the submitted work, membership of the steering committee of the HEAT study (NIHR HTA funded), membership of a data monitoring committee (Novartis) and is a trustee of the Scottish Heart and Arterial disease Risk Prevention (SHARP) Society. Filippo Pigazzani, Suzanne Duce, Rebecca Barr, Jennifer Dumbleton, Evelien Rooke, Jonathan Townend and Lewis Ritchie declare no competing interests.

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Crossmark status check

Report Content

The full text of this issue is available as a PDF document from the Toolkit section on this page.

The full text of this issue is available as a PDF document from the Toolkit section on this page.

If you would like to receive a notification when this project publishes in the NIHR Journals Library, please submit your email address below.

Responses to this report

No responses have been published.

 

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors.  Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

By submitting your response, you are stating that you agree to the terms & conditions

An error has occurred in processing the XML document